Rapport Synthèse de la Première Réunion Trimestrielle des Directeurs Régionaux et Préfectoraux de la santé dans les Zones Appuyées par PMI en Guinée Pour la Restitution de l’enquête euv et l’analyse des Rapports de Gestion de Produits Antipaludiques Conakry le 12 au 14 Mars 2013
The Ministry of Health, through the Department for the Health of Families and Specific Groups (D10), organized a workshop on August 29–30, 2013, to sensitize policy makers and operational partners. This resulted in development of the outline for a strategic plan for the introduction and use of 7.1 percent CHX for umbilical cord care in … Read more
Poor availability of pharmaceutical and surgical supplies was experienced in the latter part of 2011 at hospitals and primary health care centers (PHCs) in Bojanala District, one of the four districts in the North West Province. This resulted in the decision to conduct a comprehensive survey within the district to determine reasons for the shortages … Read more
The Ministry of Health (Ministério da Saúde; MINSA)’s National Directorate of Medicines and Equipment (Direccao Nacional de Medicamentos e Equipamentos; DNME) is responsible for regulating medicines and other pharmaceutical products in Angola in collaboration with the Inspectorate General of Health (Inspecção-Geral da Saúde; IGS). Preliminary reports indicated that the regulatory system was not fully functional … Read more
This report briefly describes the major activities that SIAPS carried out at the global level as well as in Angola, Burundi, the Democratic Republic of the Congo, Ethiopia, Guinea, Liberia, Mali, and South Sudan between January and March 2013.
In 2004 the MSH-implemented RPM Plus Program supported the MoHSS in carrying out a baseline assessment of pharmaceutical management information and monitoring systems in Namibia. The key objective of this assessment was to determine “the capacity of the local government to meet medicine and other health commodity needs in support of the launch and establishment … Read more
This document addresses how to develop a universally adaptable plan to reduce or prevent harmful effects from the use of anti-TB medicines, and to promote their efficient utilization. This process will require the development and implementation of risk management plans and tools to promote patient safety.
This document presents an overall M&E plan for the SIAPS Program. It will serve as a blueprint for assessing the outcomes of the full scope of SIAPS’ activities. The realization of the ability to assess our results depends on the development and execution of individual portfolio M&E plans that will contribute to the data requirements … Read more
The world’s response to the AIDS pandemic of dramatically increased financial assistance to provide affordable medicines for HIV and AIDS did not automatically lead to access to antiretrovirals (ARVs). The effectiveness of these multimillion dollar initiatives was recognized to be limited by the capacity of the health care and pharmaceutical supply systems to deliver these … Read more
